Locations:
SearchAdvertisement
Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression
What’s coming up at ASH and beyond
Retrospective study evaluates clinical upstaging during neoadjuvant treatment
Retrospective study finds acceptable cancer control among most histologic subtypes with intravesical therapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Machine learning models assess intraoperative tissue perfusion
Combining mind, body and lifestyle practices in alignment with conventional cancer treatment
Higher type 2 immunity observed in persistent CAR T cells
Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children
Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers
Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma
Advertisement
Advertisement